Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the fi rst 15 years after diagnosis. We aimed to assess the further eff ects of continuing tamoxifen to 10 years instead of stopping at 5 years.
Introduction
For women with oestrogen receptor (ER)-positive breast cancer, treatment for 5 years with adjuvant tamoxifen substantially reduces the rate of recurrence not only during the treatment period but throughout the fi rst decade, and reduces breast cancer mortality by about a third throughout the fi rst 15 years (including years [10] [11] [12] [13] [14] , with little net eff ect on other mortality. 1 Although 5 years of tamoxifen is more eff ective than is 1-2 years of treat ment, 1,2 whether 10 years of treatment would have an even greater eff ect on breast cancer recurrence and mortality in ER-positive disease is not known. 3, 4 Conversely, treatment with 5 years of tamoxifen can cause side-eff ects such as endometrial cancer and thromboembolic disease, 1, 5 and continuing tamoxifen for an additional 5 years is likely to increase these side-eff ects.
Early trials of continuing adjuvant tamoxifen to 10 years versus stopping tamoxifen at 5 years [6] [7] [8] recruited relatively few patients. Although some of these studies had adverse early results, 9 the small numbers of patients meant that these adverse results could have been due to the play of chance, so larger trials were needed. 3, 4, 10 Moreover, as 5 years of tamoxifen has a prolonged carryover eff ect after treatment ends, with a substantial reduction in mortality throughout the fi rst 15 years, trials of continuing beyond 5 years of tamoxifen should eventually be followed up to beyond 15 years. 4 The UK adjuvant Tamoxifen-To off er more? (aTTom) trial randomly allocated 7000 women, most with unknown ER status, to continue tamoxifen to 10 years or stop at 5 years, but has yet to report long-term fi ndings. [11] [12] [13] We report results from the global Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, which randomly allocated 12 894 women to continue tamoxifen to 10 years or stop at 5 years. Our main analyses of breast cancer outcomes involve only the 6846 women with ER-positive disease (sensitivity analyses shown in the appendix include the other women); side-eff ect analyses include all 12 894 women, regardless of whether the ER status of their disease was positive, negative or unknown.
Methods

Study design and participants
ATLAS is an international trial of continuation of adjuvant tamoxifen for an extra 5 years. Women were eligible for randomisation if they had had early breast cancer (in which all detected disease could be removed); they had subsequently received tamoxifen for some years and were still on it (or had stopped in the past year and could resume treatment with little interruption); they appeared clinically free of disease (with any local recurrence removed and no distant recurrence detected); follow-up seemed practicable; and substantial uncertainty was shared by the woman and her doctor as to whether to stop tamoxifen or continue for about 5 more years. No restrictions were placed on age, type of initial surgery or histology, hormone receptor status, nodal status, or other treatments.
Any contraindications to continuation of tamoxifen precluded entry; clinicians were responsible for assessment of these contraindications, which were not protocoldefi ned. However, the protocol did suggest clinicians consider pregnancy, breastfeeding, retinopathy, need for coagulation therapy, endometrial hyperplasia, other serious toxicity attributed to tamoxifen, negligibly low risk of death from breast cancer, or presence of another lifethreatening disease as possible contraindications.
ATLAS recruited patients from 36 countries or regions during 1996-2005. In general, each country or region had a coordinator on the international steering committee who liaised with collaborators at local hospitals to help ensure eligible patients were considered and, if entered, treated and followed up appropriately. Ethical approval was provided by the Oxford Tropical Research Ethics Com mittee, national and regional ethics committees where applicable, and local ethics committees in each hospital. Patients were off ered information leafl ets in local languages. After patients provided signed consent, base line characteristics were recorded and patients were entered into the study by post, telephone, or fax to the Oxford Clinical Trial Service Unit (CTSU) or to four national or regional centres (listed at the end of the paper). Forms were stored in the CTSU, with copies at local hospitals.
When ATLAS began in 1996, 2 years and 5 years of tamoxifen were both standard treatment options, 14 so patients were eligible irrespective of previous duration of tamoxifen treatment. Shortly afterwards, a consensus emerged that 5 years of treatment was better than 2 years of treatment. 2, 10 Entry with less than 4 years of previous tamoxifen (and, in most countries, of women with ER-negative disease) was therefore stopped in 2000, before ATLAS had meaningful results. The women who had entered ATLAS after less than 4 years of tamoxifen will be reported separately within an update of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analyses 2 of longer treatment versus about 2 years of treatment (fi gure 1). This report is of the remain ing women; as they had completed a 
Randomisation
The CTSU or the four regional or national centres used CTSU software to allocate eligible women randomly to continue tamoxifen to 10 years (stopping only if a definite contraindication emerged) or to stop tamoxifen immediately at 5 years (open control). No placebo treatment was used among controls, and tamoxifen was restarted only if a defi nite indication was thought to have emerged. Randomisation was minimised 1:1 to balance treatment allocation by country or region and by major prognostic factors (age group, node negativity, tumour diameter, and ER status).
Procedures
Other than duration of tamoxifen treatment, patient manage ment was at the responsible clinician's discretion. The tamoxifen regimen before and during ATLAS was almost always Nolvadex 20 mg per day; where tamoxifen was not aff ordable, free Nolvadex was provided by the study. Patients were not required to make any extra visits, and no extra investigations were required. Central organisers sent forms to responsible clinicians every year asking about use of tamoxifen or other adjuvant endocrine treatments, breast cancer recurrence, new primary cancer incidence (particularly endometrial cancer), reasons for any hospital admissions (particularly hysterectomy and myocardial infarction), and, if the patients had died, underlying cause of death (asking particularly about breast cancer, endometrial cancer and myocardial infarction); death certifi cates were also sought. Recurrence was defi ned as fi rst recurrence after ATLAS entry of any breast cancer (new or same tumour, distant [including unspecifi ed or multiple sites], loco regional, or contralateral). Yearly follow-up forms might report only the worst new endpoint, so if no recurrence had been recorded before a death from breast cancer (or if only contralateral or locoregional recurrence had been recorded before a death), we assumed distant recurrence just preceded death. Deaths from unknown causes without any recorded recurrence were regarded as unrelated to breast cancer. Events were coded, generally in ignorance of (but not masked to) treatment allocation, by the ATLAS principal investigator (CD) according to the 10th International Classifi cation of Diseases (ICD-10). 15 Data errors were sought centrally by extensive manual or computer checks, and investigated.
Although 6846 (53%) of 12 894 women had ER-positive disease, 4800 (37%) had unknown ER status. A retrospective project sought missing ER values, but the project was soon abandoned (because sample retrieval and assays diff ered between women still attending hospital for continued tamoxifen and those who had stopped treatment). The retrospective assay results from this project are not included in the main analyses, although the assays that were done supported reports 16 that ERpositivity is substantially less common in Asia than in Europe. (Many ER-untested samples were from Asia, suggesting that only about 60% of all ER-untested samples would, if tested, have been ER-positive; appendix p 26).
Until mid-2010, when the last trial treatment ended, yearly interim analyses (split by ER status) of recur rence, death with recurrence, and cause-specifi c mortality before recurrence were sent to an independent data monitoring committee. 
Statistical analysis
The protocol stated that 20 000 patients would need to be randomised in ATLAS and the other trials of tamoxifen duration to detect reliably an absolute diff erence of 2-3% in mortality. Entry to ATLAS was halted in 2005 (with 12 894 patients, including 6846 with ER-positive disease) because the MA.17 trial 17 showed benefi t from continued endocrine treatment after 5 years of tamoxifen. We report the dataset of Aug 31, 2012, because in September, 2012 this dataset was supplied to help update the periodic EBCTCG metaanalyses of all tamoxifen duration trials, 2 which will eventually become public. After this preliminary report, further follow-up of ATLAS will continue. Intention-to-treat log-rank analyses, using in-house programs, yield the event rate ratio (RR; also known as risk ratio) and its standard error, the CI, and the twosided p value. 1, 2, 18 If a log-rank statistic (observed -expected [O -E]) from a main or sensitivity analysis has variance V, then RR = exp([O -E] / V). Kaplan-Meier graphs show absolute risks during years 5-14. Analyses (of the fi rst relevant event since entry) were of: recurrence (censored at death from other causes), side-eff ects (censored at recurrence), breast cancer mortality, and overall mortality. Breast cancer mortality analyses subtracted the log-rank statistics for death without recurrence from those for overall mortality 1,2 (without assuming all recur rences are equally life-threatening).
We used data for all patients with ER-positive, ERnegative, or ER-untested disease to assess side-eff ects, but data for patients with ER-negative or ER-untested disease cannot contribute directly to assessment of eff ects in ER-positive disease. Therefore, the main empha sis in this report is on non-breast-cancer outcomes in all 12 894 women, but on recurrence and breast cancer mortality only in the 6846 women with ER-positive disease (as in the recent EBCTCG meta-analyses of tamoxifen trials 1 ).
In addition, sensitivity analyses (appendix pp 14-18) combine results in ER-positive and ER-untested disease (taking the eff ect in ER-untested to be 60% of that in ERpositive disease; appendix p 26) by adding 0·6 times the log-rank (O -E) statistic for ER-untested disease to that for ER-positive disease, changing the variance V accordingly, then again using RR = exp(
The protocol-defi ned main analysis (appendix pp 27-49) was of all-cause mortality in all women, irrespective of ER status or previous tamoxifen duration; this analysis is provided. The questions that still need answering about tamoxifen duration have, however, changed since ATLAS began, and the main analyses in the present paper are in line with those changes. Negative ER measurements are known to identify reliably patients with little or nothing to gain from tamoxifen. Moreover, for patients with ERpositive disease, 5 years of tamoxifen is known to be better than 2 years of tamoxifen (although the full benefi ts take at least 15 years to emerge), and 5 years of tamoxifen has little net eff ect o n mortality not caused by breast cancer (despite specifi c side-eff ects such as endometrial cancer). 1, 2 Therefore, the main issue is how, in ER-positive disease, 10 years of treatment compares with 5 years of tamoxifen in terms of main eff ects on recurrence and breast cancer mortality, and how the specifi c side-eff ects of 10 years and 5 years of tamoxifen diff er. 1, 2, 10 If the aim is to assess eff ects on breast cancer outcomes in ER-positive disease, analyses need to be based either on the fi ndings in patients known to have ER-positive disease (which are straightforward to present and are provided in full) or on a combination of the fi ndings in ER-positive and ER-untested disease (which are provided as sensitivity analyses). Emphasis on breast cancer outcomes only in ER-positive disease was proposed by the data monitoring committee statistician (RP) who knew the ATLAS results, but the results from the main and sensitivity analyses were much the same: appendix pp 14-18.
This study is registered, number ISRCTN19652633.
Role of the funding source
Oxford University (Oxford, UK) was the trial sponsor. The study was designed, conducted, analysed, interpreted and reported by the investigators independently of all funding bodies (who saw the manuscript only after acceptance). CD, HP, JG, RG, and RP had full access to all data and had fi nal responsibility for the decision to submit for publication. Figure 1 describes the diff erent populations that were analysed to assess the side-eff ects and the main eff ects of continuing tamoxifen to 10 years versus stopping tamoxifen at 5 years. After exclusion of 18 women who had been entered in error and 2350 women who had completed a median of only 2·4 years (IQR 2·0-3·1) of adjuvant tamoxifen, 12 894 women remained who had completed a median of 5·0 years (4·8-5·2) of adjuvant tamoxifen. All were included in the analyses of sideeff ects, regardless of ER status. After exclusion of a further 6048 women with ER status unknown or with ER-negative disease, 6846 women with ER-positive disease remained for the main analyses of the eff ects on breast cancer recurrence and breast cancer mortality. Table 1 shows the characteristics of the included patients. Figure 2 shows compliance with the trial treatment allocation. Among women who were without recurrence 2 years after entry (ie, at year 7 after diagnosis), 84% of those allocated to continue were still on tamoxifen compared with 4% of controls, a diff erence of 80%. Fewer than 1% of women were receiving any adjuvant endocrine treatment other than tamoxifen. Figure 2 also shows that the completeness of follow-up was similar in both treatment groups. In each group 91% of the survivors were still being followed up 10 years after diagnosis and 77% were still being followed up 15 years after diagnosis; these proportions will increase as more follow-up accumulates. Some incompleteness was due to a few centres withdrawing and stopping all follow-up in both treatment groups. Nine patients allocated to continue tamoxifen and ten controls withdrew consent to further follow-up, but their earlier follow-up is included. Log-rank analyses by allocated treatment, censored at the last available record, allow for any incompleteness of follow-up, yielding treatment comparisons with no material bias (especially as incompleteness did not diff er between the two treatment groups).
Results
We recorded 1328 recurrences (899 during years 5-9, 379 during years 10-14, and 50 after reaching year 15). Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of recurrence (617 recurrences in 3428 women allocated to continue vs 711 in 3418 controls; RR 0·84, 95% CI 0·76-0·94; p=0·002), reduced breast cancer mortality (331 deaths with recurrence in women allocated to continue vs 397 in controls, p=0·01) and reduced overall mortality (639 deaths vs 722 deaths, p=0·01). The risk of recurrence during years 5-14 was 21·4% for women allocated to continue versus 25·1% for controls (absolute recurrence reduction 3·7%); fi gure 3. There was no evidence of a rebound increase in the recurrence rate when tamoxifen treatment ended. Breast cancer mortality during years 5-14 was 12·2% for women allocated to The log-rank analyses of death with recurrence are done by subtraction of the log-rank analyses of death without recurrence from those of any death. If O -E is negative, its value is about half the number of events prevented; if V is its variance, event rate ratio is exp([O -E] / V). ER=oestrogen receptor. *Two-sided. †In parentheses: number of women allocated to continue tamoxifen vs number allocated to control. ‡Delay of recurrence by continuation of tamoxifen increases woman-years at risk before recurrence by about 3% in ER-positive disease; the log-rank analyses allow for this, but crude comparisons of total numbers of events before recurrence do not. §Mainly heart disease, but includes all vascular causes apart from stroke and pulmonary embolus. ¶Mainly endometrial adenocarcinoma, but includes all other uterine tumours apart from cervical cancer; analyses of uterine tumour incidence exclude women with hysterectomy recorded at trial entry. Table 2 : Eff ects of allocation (continue tamoxifen to 10 years vs stop at 5 years) on mortality with and without previous recurrence in each category of ER status at entry, and on various outcomes without previous recurrence in all women of any ER status continue versus 15·0% for controls (absolute mortality reduction 2·8%). The main eff ects on recurrence and, particularly, on breast cancer mortality became apparent only during the second decade after diagnosis (fi gure 3). For recurrence, the RR was less extreme during years 5-9 (0·90, 95% CI 0·79-1·02; p=0·10) than after reaching year 10 (0·75, 0·62-0·90; p=0·003), but the heterogeneity between the RRs in the two time periods was not signifi cant (p=0·10). For breast cancer mortality the RR was again less extreme during years 5-9 (0·97, 0·79-1·18; p=0·74) than after reaching year 10 (0·71, 0·58-0·88; p=0·0016), and the heterogeneity between the mortality RRs in the two time periods was signifi cant (p=0·04).
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To date, twice as many recurrences have been recorded during the fi rst 5 years as during the second 5 years after randomisation, so taking all time periods together the overall recurrence RR in ER-positive disease is dominated by the fi rst 5 years. Figure 4 shows various subgroup analyses for this overall result, with no signifi cant heterogeneity of the proportional risk reduction with respect to patient or tumour characteristics or site of fi rst recurrence. The reduction in distant recurrence is not separately signifi cant in fi gure 4 (p=0·12 for distant recurrence as fi rst event, but p=0·05 for distant recur rence at any time; appendix p 20). Table 2 subdivides by ER status the eff ects of the treatment allocation on mortality with and without recurrence. For death with recurrence, the eff ect of the treatment allocation in ER-unknown disease seems to be intermediate between the signifi cant eff ect already described in ER-positive disease and the lack of apparent eff ect in ER-negative disease.
Sensitivity analyses that use the intermediate treatment eff ects in ER-unknown disease to help estimate the treatment eff ects in ER-positive disease did not materially alter the estimated RRs for breast cancer outcomes in all time periods (appendix pp 14-18), but made the p values for them somewhat more extreme (recurrence p=0·0009, distant recurrence at any time p=0·02, breast cancer mortality p=0·004, and all-cause mortality p=0·011).
For death without recurrence in all 12 894 women, irrespective of ER status, there was no signifi cant eff ect of the treatment allocation, either overall or for death from any particular cause (table 2). In the hypothetical absence of any breast cancer mortality, the probability of dying from another cause during years 5-14 after breast cancer diagnosis would be 5% for women younger than 60 years at entry and 20% for older women. Table 2 also describes various other events without previous recurrence in all women. For the incidence (hospitalisation or death) rates of specifi c diseases, RRs were: pulmonary embolus 1·87 (95% CI 1·13-3·07, p=0·01 [including 0·2% mortality in both treatment groups]), stroke 1·06 (0·83-1·36, p=0·63), ischaemic heart disease 0·76 (0·60-0·95, p=0·02), and endometrial cancer 1·74 (1·30-2·34, p=0·0002 [including all non-cervical uterine cancers]). The cumulative risk of endometrial cancer during years 5-14 was 3·1% (mortality 0·4%) for women allocated to continue tamoxifen versus 1·6% (mortality 0·2%) for controls (absolute mortality increase 0·2%).
Discussion
Previous trials have shown that, for women with ERpositive early breast cancer, 5 years of adjuvant tamoxifen substantially reduces recurrence rates throughout the fi rst 10 years after diagnosis and substantially reduces breast cancer mortality throughout the fi rst 15 years. 1 Thus, the eff ects of 5 years of treatment with tamoxifen on annual rates of mortality persist for at least a decade after treatment ends. Because of this carryover benefi t after only 5 years of tamoxifen, it was already recognised 4 when ATLAS began that there could well be little additional benefi t during the fi rst few years of additional treatment, even if worthwhile benefi t would emerge later. With an average of 7·6 woman-years of further follow-up after entry at 5 years, the fi ndings thus far available conform with these expectations. ATLAS has now shown that, compared with stopping after only 5 years of tamoxifen, continuing for another 5 years (to 10 years) provides further protection against recurrence and breast cancer mortality, particularly after reaching 10 years. Table 2 includes the prespecifi ed protocol analysis of overall mortality in all women in ATLAS irrespective of ER status, but this is less informative than are the main analyses in the present report of breast cancer outcomes in women with ER-positive disease. Inferences about the eff ects of tamoxifen on recurrence and on breast cancer mortality in ER-positive disease can be made either from these main analyses or from the sensitivity analyses involving ER-untested disease (appendix pp [14] [15] [16] [17] [18] , although these sensitivity analyses are somewhat dependent on the assumed proportion that would have been ER-positive if tested. Irrespective of whether the main or the sensitivity analyses are preferred, the results are similar. Moreover, as follow-up was equally thorough in both treatment groups, ascertainment of mortality (particularly after treatment ends) is not materially biased by controls not having been given placebo tablets.
By combining results from the previous trials 1 with the new results from ATLAS, we can estimate what would be seen in trials of 10 years of adjuvant tamoxifen compared with no treatment. Table 3 provides, by time since diagnosis, the recurrence RRs from the trials of 5 years of tamoxifen versus no tamoxifen and from the ATLAS trial of con tinuing tamoxifen to 10 years versus stopping at 5 years, and multiplies these RRs together to estimate what would be seen in trials of 10 years of tamoxifen versus no tamoxifen. Table 3 also provides similar estimates for breast cancer mortality. The recurrence and, particularly, the mortality fi ndings are remarkable, and suggest that in trials of 10 years of tamoxifen versus no tamoxifen, breast cancer mortality rates during the second decade after diagnosis would be almost halved, although the real fi nding is not the point estimate but the CI (which shows that the reduction could be as little as a third rather than a half).
However, both in trials of 5 years of tamoxifen 1 and in ATLAS, there was a diff erence of only about 80% between the prevalence of tamoxifen use in the two treatment groups, so the estimates in table 3 are likewise of what would be seen in trials of 10 years of tamoxifen compared with no tamoxifen that had only about 80% compliance. The risk reduction achievable by full compliance with 10 years of tamoxifen should, therefore, be appreciably greater, strengthening the conclusion that breast cancer mortality during the second decade after diagnosis (or at least during years [10] [11] [12] [13] [14] can be approximately halved. Thus, good evidence now exists that 10 years of tamoxifen in ER-positive disease produces substantial reductions in rates of recurrence and in breast cancer mortality not only during the fi rst decade (while treatment continues) but also during the second decade (after it ends).
Continued follow-up of ATLAS will eventually yield further evidence about eff ects on breast cancer outcomes during the second decade after diagnosis. Before then, substantial additional information about events during the second decade will have been contributed by the other trials of continuing tamoxifen to 10 years versus stopping at 5 years (particularly aTTom, the UK counterpart of ATLAS, which reported little benefi t during years 5-9 but has not yet reported on outcomes during the second decade 13 ). EBCTCG meta-analyses of ATLAS, aTTom, and the smaller trials will eventually clarify the eff ects on breast cancer outcomes 10-14 years after diagnosis (panel).
Tamoxifen produces favourable lipid profi le changes 19-21 and the ATLAS results do suggest some protection against ischaemic heart disease. Because, however, no signifi cant protection against heart disease was seen in trials of tamoxifen versus no tamoxifen, 1,2 the apparent reduction in ATLAS might be largely a chance fi nding (especially since the apparent protection was against events after the treatment period, and long-term follow-up of trials of cholesterol-lowering statin treatment fi nd little further benefi t after treatment ends 22 ). Conversely, although the US Food and Drug Administration lists stroke as a possible side-eff ect, 5,23 no apparent increase in stroke incidence or mortality was seen during the treatment period either in ATLAS or in the trials of 5 years of tamoxifen. 1 However, defi nite long-term side-eff ects of tamoxifen do exist, which require longer follow-up and metaanalyses of all relevant trials for fi nal assessment. In both ATLAS and the trials of 5 years of tamoxifen versus no treatment, 1,2 tamoxifen increases the incidence of endometrial cancer in postmenopausal women who had not had a hysterectomy before trial entry. Although there is little risk in premenopausal women, life-table calculations for older women (together with allowance for the imperfect compliance with treatment allocations in trials) suggest that actual use of 5 years of adjuvant tamoxifen would produce an absolute 15 year endometrial cancer risk of about 2-3%, 1 and that use of 10 years rather than 5 years of tamoxifen would produce an additional risk by year 15 of about 2%.
The death rate from endometrial cancer was, however, only about a tenth of the incidence rate, suggesting that full compliance with 10 years of tamoxifen in postmenopausal women would produce a 15 year risk of a few per thousand of eventually dying from the excess of uterine cancer. This risk is greatly outweighed in ER-positive disease by the decrease in breast cancer mortality.
Panel: Research in context
Systematic review
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) periodically reviews trials of adjuvant tamoxifen versus no tamoxifen in early breast cancer and of longer versus shorter tamoxifen durations. The EBCTCG's meta-analyses 1, 2 show that, in oestrogen receptor (ER)-positive disease, 5 years of adjuvant tamoxifen substantially decreases breast cancer recurrence, breast cancer mortality, and overall mortality (despite small absolute increases in endometrial cancer and pulmonary embolus). Previous trials have not, however, answered the question of how 10 years of tamoxifen compares with only 5 years. Because the decrease in breast cancer mortality produced by 5 years of tamoxifen continues to be substantial for a decade after treatment ends (ie, throughout the fi rst 15 years after diagnosis), trials of 10 years versus 5 years of tamoxifen will need to be followed up for at least 15 years from diagnosis.
Interpretation
The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, with a mean of 7·6 years of further follow-up after entry at year 5, shows that recurrence and breast cancer mortality during the second decade after diagnosis are reduced more eff ectively by 10 years of adjuvant tamoxifen than by 5 years. Although known side-eff ects were increased (at least in postmenopausal women) by longer treatment, the absolute reduction in breast cancer mortality was an order of magnitude greater than the absolute increase in mortality due to these side-eff ects. Taken together with the results from trials of 5 years of tamoxifen versus none, the results from ATLAS show that 10 years of eff ective endocrine therapy can approximately halve breast cancer mortality during years 10-14 after diagnosis. Longer follow-up of ATLAS (and a meta-analysis of all such trials) will be needed to assess the full benefi ts and hazards throughout the second decade. For tamoxifen, 10 years of treatment has greater protective eff ects against ER-positive breast cancer than does 5 years of treatment, so the same might well be true for any comparably eff ective endocrine treatment, either with another selective oestrogen receptor modifi er or, in postmenopausal women, with an aromatase inhibitor. 24 In both cases, 10 years of treatment should be expected to have a greater protective eff ect than 5 years of treatment would have, although other endocrine treatments can, like tamoxifen, also have long-term side-eff ects.
For premenopausal women with continued ovarian activity, however (among whom aromatase inhibitors are not an alternative to tamoxifen), there is little risk of tamoxifen causing uterine cancer or vascular side-eff ects to counterbalance the large absolute reduction in breast cancer mortality. Hence, our results are particularly relevent to premenopausal women with ER-positive disease-and, young women protected by 10 years of tamoxifen from death from breast cancer gain several decades of life expectancy.
